Repros (RPRX) to Begin Enrolling in Second Androxal Phase 3 After Completion of ZA-301
Tweet Send to a Friend
Repros Therapeutics Inc. (Nasdaq: RPRX) today provided a clinical update of its Androxal Phase 3 program.
Pivotal Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Pivotal Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
